Stocks in Focus (ATHX,GPOR,OSTK,SRNE)

Markets are looking grim @ 2,728.62 −61.20 (2.19%). However, there are some stocks that are still making waves.

Athersys Inc (NASDAQ:ATHX): The company granted today morning that it was granted approval by the Food and Drug Administration (FDA) to start a pivotal clinical study of its stem-cell therapy on patients with COVID-19-induced acute respiratory distress syndrome (ARDS). This means that the company can now initiate their phase 2/3 study involving covid-19. Considering recent negative press article in seeking alpha, the shorts may potentially get squeezed out and retest the mid to upper $3’s soon.

Gulfport Energy Corporation (GPOR) (NASDAQ:GPOR): Pomerantz LLP announces that a class action lawsuit has been filed against Gulfport Energy Corporation (“Gulfport” or the “Company”) (NASDAQ:  GPOR) and certain of its officers. GPOR is an independent oil and gas company. Oversold sector with high short interest. Maybe moves up to test $1 soon., Inc. (OSTK) (NASDAQ:OSTK): Reportedly getting better than expected sales numbers from, which is in a sector that has been outperforming. Also, special dividend coming up with ex-dividend date of April 24th. Nice catalysts, could go retest upper $9’s.

Sorrento Therapeutics Inc (NYSE:SRNE): The FDA approved Celularity’s Investigational New Drug (IND) application for the use of CYNK-001, its natural killer (NK) cell-based immunotherapy candidate to treat critically and severely ill patients with COVID-19. This means that Celularity can kick off a Phase 1/2 study with up to 86 patients.Nice bull flag chart pattern after finally Press Releasing their involvement with Covid-19. Might go test upper $2’s to $3 on a green market day.